The MMJ International Holdings, MMJ BioPharma Cultivation, MMJ Biopharma Labs, has manufactured its THC (tetrahydrocannabinol) and CBD (cannabidiol) medicine for the treatment of Multiple Sclerosis and Huntington's Disease in human clinical trials.
MMJ is one of a few companies that are following FDA guidelines in the development of their pharmaceutical THC, CBD soft-gelatin capsule for human consumption in to be FDA approved clinical trials.
Duane Boise, the company's president stated "Following federal guidelines and obtaining FDA approval for such trials is an important milestone in ensuring the safety and efficacy of this new cannabis pharmaceutical product".
Dr. Elio Mariani stated, "It's worth noting that while cannabis remains classified as a schedule I controlled substance at the federal level, there has been growing interest in researching its potential medical benefits. In the case of MMJ, the FDA should release its clinical hold for its medicine to be used in clinical trials. MMJ has adhered to the current strict federal regulatory requirements."
When MMJ International Holdings receives FDA approval to conduct human clinical trials using its medicine derived from the cannabis plant, it will be a significant development in the field of medical cannabis research and pharmaceuticals.
For more information:
MMJ BioPharma Cultivation
www.mmjbiopharma.com